Non Small Cell Lung Cancer Market Size, Share | Report 2031

Report Description

Non-small Cell Lung Cancer Market Outlook 2031:

The global non-small cell lung cancer market size was valued at USD 16.72 Billion in 2022 and is projected to reach USD 37.22 Billion by 2031, expanding at a CAGR of 9.3% during the forecast period 2023 - 2031, attributed to the wide prevalence of lung cancer and increasing cases of HIV infection. The growth of the non-small cell drug cancer market is also attributed to the global increase in the population base.

Lung cancer is categorized into two types namely small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). The most number of lung cancer cases falls under the category of non-small cell lung cancer. When cancer cells start to form in the lung tissues, it is called non-small cell lung cancer.

Get Free Sample Report

Some of the most commonly occurred symptoms are coughing up blood, chest pain, hoarseness, wheezing, loss of appetite, weight loss, shortness of breath, recurring bronchitis, fatigue, numbness of limbs, and difficulty in swallowing. Lung cancer can also be caused due to continued smoking cigars or pipes and cigarettes.  

As per the report by Cancer Research 2017, among the total 87% of the cancer patients present in the UK were non-small cell lung cancer patients. According to the report in 2019 by American Society of Clinical Oncology, 13% of all the new cancer diagnosis was related to lung cancer.

The reports by the UK CancerResearch also stated that the number of cancer patients was increasing globally and expected to increase further in the near future. The reports estimated that if the growth rate of the cancer was at the same pace, the 27.5 million new global cancer cases were estimated to be reported by 2040.

Non-small Cell Lung Cancer Market Trends, Drivers, Restraints, and Opportunities

• Rapid industrialization and increasing number of smokers globally are leading to sharp increase in air pollution. This is a key driver helping to grow the market.
• Presence of well-structured and well-developed healthcare systems in various developed regions are expected to fuel the non-small cell lung cancer market growth in the coming years.
• High cost of therapies and side effects caused by the existing drugs are acting as major restraints anticipated to impede the market growth during the forecast period.
• Lack of awareness among people regarding non-small lung cancer is another key challenge that can hinder the non-small cell lung cancer market growth.
• Ongoing research & development programs and growing investment in the development & launch of new products across the globe are estimated to present key opportunities for the non-small cell lung cancer market expansion.

^{Scope of Non-small Cell Lung Cancer Market Report}

The report on the global non-small cell lung cancer market includes an assessment of the market, trends, and segments. Overview and dynamics have also been included in the report.

Market Segment Insights

Large cell carcinoma segment is expected to dominate the market

On the basis of histology, the global non-small cell lung cancer market is categorized as large cell carcinoma, squamous cell carcinoma, and adenocarcinoma. The large cell carcinoma segment is expected to dominate the market during the forecast period since it can occur at any part of the lungs and is difficult to cure.

Meanwhile, squamous cell carcinoma takes place in the middle of the lungs at squamous cells near the bronchus, and adenocarcinoma occurs at the outer parts of the lungs in the cells which secrets mucous. On the other hand, the adenocarcinoma segment is projected to grow at moderate rate when compared to the other two types.

Get Free Sample Report

Chemotherapy segment is anticipated to hold a key share of the market

Based on treatments, the non-small cell lung cancer market share is segmented into chemotherapy, surgery, and radiation. The chemotherapy segment is anticipated to hold a key market share during the projected period owing to wide performed of the treatment method on a number of major therapies of cancer patients and wide availability of strong clinical performance.

The use of platinum combination therapy is suggested by the American Society for Clinical Oncology for the treatment of first-line non-small cell lung cancer. For the first two phases of non-small cell, lung cancer surgery is used for its treatment. However, when surgeries are not possible for the first and second phase, then radiation is preferred to as the major treatment process. Due to which, the segment is projected to exhibit a high CAGR during the forecast period.

Get Free Sample Report

North America is projected to represent a substantial share

In terms of regions, the global non-small cell lung cancer market share is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is projected to represent a substantial share of the market during the targeted period owing to early acceptance of innovative diagnostic techniques and wide adoption of advanced treatment devices by major players in the region.

The market of North America is followed by Europe and rising number of habitual smokers in these regions prove to be major factors for driving the market. On the other hand, the market of Asia Pacific is expected to contribute a considerable market share in the coming years attributed to the wide prevalence of the disease in the region.   

Get Free Sample Report